Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

Published:2014-12-09 Issue:9 Volume:121 Page:1414-1421
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Klaassen Zachary¹,Singh Abhay A.²,Howard Lauren E.²³,Feng Zhaoyong⁴,Trock Bruce⁴,Terris Martha K.¹⁵,Aronson William J.⁶⁷,Cooperberg Matthew R.⁸⁹,Amling Christopher L.¹⁰,Kane Christopher J.¹¹¹²,Partin Alan⁴,Han Misop⁴,Freedland Stephen J.²³

Affiliation:

1. Medical College of Georgia; Georgia Regents University; Augusta Georgia

2. Duke University Medical Center; Durham North Carolina

3. Durham Veterans Affairs Medical Center; Durham North Carolina

4. Johns Hopkins Hospital; Baltimore Maryland

5. Augusta Veterans Affairs Medical Center; Augusta Georgia

6. West Los Angeles Veterans Affairs Medical Center; West Los Angeles California

7. University of California Los Angeles School of Medicine; Los Angeles California

8. University of California San Francisco; San Francisco California

9. San Francisco Veterans Affairs Medical Center; San Francisco California

10. Oregon Health & Sciences University; Portland Oregon

11. University of California San Diego; San Diego California

12. San Diego Veterans Affairs Medical Center; San Diego California

Funder

National Institutes of Health

U.S. Department of Veterans Affairs

Georgia Cancer Coalition

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29147/fullpdf

Reference30 articles.

1. International variation in prostate cancer incidence and mortality rates;Center;Eur Urol.,2012

2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA.,1998

3. Prostate cancer, version 2.2014;Mohler;J Natl Compr Canc Netw,2014

4. Guideline for the management of clinically localized prostate cancer: 2007 update;Thompson;J Urol.,2007

5. Heidenreich A Bastian PJ Bellmunt J Guidelines on prostate cancer http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf 2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data;BMC Cancer;2022-06-07

2. Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy;International Journal of Clinical Oncology;2022-01-25

3. Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study;In Vivo;2022

4. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients;Frontiers in Oncology;2021-04-13

5. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options;Journal of Urology;2018-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3